Quantifying renal allograft loss following early antibody-mediated rejection

American Journal of Transplantation

Volumn 15, Issue 2, 2015, Pages 489-498

  Orandi, B J ^a   Chow, E H K ^a   Hsu, A ^a   Gupta, N ^a   Van Arendonk, K J ^a   Garonzik Wang, J M ^a   Montgomery, J R ^a   Wickliffe, C ^a   Lonze, B E ^a   Bagnasco, S M ^a   Alachkar, N ^a   Kraus, E S ^a   Jackson, A M ^a   Montgomery, R A ^a   Segev, D L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical research; epidemiology; graft survival; health services and outcomes research; kidney transplantation; nephrology; practice; rejection: antibody mediated (ABMR); Scientific Registry for Transplant Recipients (SRTR)

Indexed keywords

HLA ANTIGEN; IMMUNOGLOBULIN; PANEL REACTIVE ANTIBODY; ANTIBODY;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP ABO SYSTEM; CADAVER KIDNEY; CONTROLLED STUDY; END STAGE RENAL DISEASE; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HAZARD RATIO; HLA MATCHING; HLA SYSTEM; HUMAN; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SURGICAL PATIENT; SURGICAL RISK; ALLOGRAFT; BIOPSY; CASE CONTROL STUDY; FOLLOW UP; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOLOGY; INCIDENCE; KIDNEY; LIVING DONOR; MIDDLE AGED; PATHOLOGY; RISK FACTOR; TIME;

ADULT; ALLOGRAFTS; ANTIBODIES; BIOPSY; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMANS; INCIDENCE; KIDNEY; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS;

EID: 84921474658     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12982     Document Type: Article

References (32)

1. Bagnasco SM, Zachary AA, Racusen LC, et al. Time course of pathologic changes in kidney allografts of positive crossmatch HLA-incompatible transplant recipients. Transplantation 2014; 97: 440-445.
2. Garonzik Wang JM, Montgomery RA, Kucirka LM, et al. Incompatible live-donor kidney transplantation in the United States: Results of a national survey. Clin J Am Soc Nephrol 2011; 6: 2041-2046.
3. Massie AB, Gentry SE, Montgomery RA, et al. Center-level utilization of kidney paired donation. Am J Transplant 2013; 13: 1317-1322.
4. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.
5. Segev DL, Gentry SE, Warren DS, et al. Kidney paired donation and optimizing the use of live donor organs. JAMA 2005; 293: 1883-1890.
6. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria-An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
7. Puttarajappa C, Shapiro R, Tan HP., Antibody-mediated rejection in kidney transplantation: A review. J Transplant 2012; 2012: 1-9.
8. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684-2694.
9. Matas AJSJM, Skeans MA, Lamb KE, et al. OPTN/SRTR 2011 Annual Data Report: Kidney. Am J Transplant 2013; 13: 11-46.
10. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: Incidence and correlations. Am J Transplant 2009; 9: 1826-1834.
11. Loupy A, Loupy, A., Suberbielle-Boissel, C., et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
12. Orandi BJZA, Dagher NN, Bagnasco SM, et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection following HLA-incompatible kidney transplantation. Transplantation 2014; [Epub ahead of print].
13. Sellares J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 2013; 13: 971-983.
14. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
15. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272-283.
16. Bagnasco SM, Tsai W, Rahman MH, et al. CD20-positive infiltrates in renal allograft biopsies with acute cellular rejection are not associated with worse graft survival. Am J Transplant 2007; 7: 1968-1973.
17. Segev DL, Muzaale AD, Caffo BS, et al. Perioperative mortality and long-term survival following live kidney donation. JAMA 2010; 303: 959-966.
18. Muzaale AD, Massie AB, Wang MC, et al. Risk of end-stage renal disease following live kidney donation. JAMA 2014; 311: 579-586.
19. Schaubel DE, Dykstra DM, Murray S, et al. Analytical approaches for transplant research, 2004. Am J Transplant 2005; 5: 950-957.
20. Sharif A, Kraus ES, Zachary AA, et al. Histologic phenotype on 1-year posttransplantation biopsy and allograft survival in HLA-incompatible kidney transplants. Transplantation 2014; 97: 541-547.
21. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124-2132.
22. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532-2541.
23. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063-1071.
24. Couzi L, Araujo C, Guidicelli G, et al. Interpretation of positive flow cytometric crossmatch in the era of the single-antigen bead assay. Transplantation 2011; 91: 527-535.
25. Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: A population-based study. Lancet 2013; 381: 313-319.
26. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11: 2132-2143.
27. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582-589.
28. Higgins R, Lowe D, Hathaway M, et al. Human leukocyte antigen antibody-incompatible renal transplantation: Excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation 2011; 92: 900-906.
29. Fidler ME, Gloor JM, Lager DJ, et al. Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. Am J Transplant 2004; 4: 101-107.
30. Toki D, Ishida H, Setoguchi K, et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: Long-term impact and risk factors. Am J Transplant 2009; 9: 567-577.
31. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215-1226.
32. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.